amanda: ken feinberg, such a pleasure to have your views. rollout is one part of the equation. some countries all -- some companies are already researching cloud treatments. -- coronavirus treatments. where are you and how close to an actual market deliverable might you be? >> we announced today that we are going to be proceeding with a phase two trial. our drug therapy is different than the vaccines that are being used today and other therapies, because we focus on treating the immune system as opposed to attacking the covid virus itself. the advantage in our opinion of that approach is that the variance they keep arising every week will not be an obstacle for us in treating covid patients because our mechanism is a dampening of the immune system. in doing that, we are going after the inflammation as toac virus. matt: you are also working on multiple sclerosis treatment and you run a number of biotech's. are you impressed with the kind of progress that is being made in drugs over the past year as opposed to the decade or century previous to